Alnylam, PBL sign licensing agreement for Baulcombe & Hamilton RNAi patent

Alnylam has received world-wide, non-exclusive license to the Baulcombe patent from PBL for use in the field of human therapeutics.

Both the companies have kept the financial terms of the agreement confidential.

PBL managing director Jan Chojecki said the company looks forward to work with other partners through its non-exclusive licensing strategy in agricultural, research, diagnostic and therapeutic commercial applications.

"We are pleased to be able to make non-exclusive licences available on reasonable commercial terms to assist our partners in delivering benefits to patients in areas of unmet medical need," Chojecki added.

Alnylam’s IP estate includes issued, allowed, or granted fundamental patents in several pharmaceutical markets that claim the structural and functional properties of RNAi therapeutic products.